

Tarina L. Kang

Tiffany M. Abramson

## REFERENCES

- Kiernan MC, Vucic S, Cheah BC, et al: Amyotrophic lateral sclerosis. *Lancet* 377: 942, 2011. [PMID: 21296405]
- Naganska E, Matyja E: Amyotrophic lateral sclerosis—looking for pathogenesis and effective therapy. *Folia Neuropathol* 49: 1, 2011. [PMID: 21455838]
- Gordon PH: Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. *CNS Drugs* 25: 1, 2011. [PMID: 21128691]
- Hardiman O, van den Berg LH, Kiernan MC: Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nat Rev Neurol* 7: 639, 2011. [PMID: 21989247]
- Pratt AJ, Getzoff ED, Perry JJ: Amyotrophic lateral sclerosis: update and new developments. *Degener Neurol Neuromuscul Dis* 2012(2): 1-14, 2012. [PMID: 23019386]
- Hardiman O, van den Berg LH, Kiernan MC: Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nat Rev Neurol* 7(11): 639, 2011. [PMID: 21989247]
- Kaufmann P, Levy G, Montes J, et al: Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. *Amyotroph Lateral Scler* 8: 42, 2007. [PMID: 17364435]
- Agosta F, Chiò A, Cosottini M, et al: The present and the future of neuroimaging in amyotrophic lateral sclerosis. *Am J Neuroradiol* 31: 1769, 2010. [PMID: 20360339]
- Miller RG, Mitchell JD, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 3: CD001447, 2012. [PMID: 22419278]
- Miller RG, Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 1: CD001447, 2007. [PMID: 17253460]
- Miller RG, Jackson CE, Kasarskis EJ, et al: Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. *Neurology* 73: 1218, 2009. [PMID: 19822872]
- Andersen PM, Abrahams S, Borasio GD, et al: EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. *Eur J Neurol*, 19(3): 360, 2012. [PMID: 21914052]
- Chen A, Montes J, Mitsumoto H: The role of exercise in amyotrophic lateral sclerosis. *Phys Med Rehabil Clin North Am* 19: 545, 2008. [PMID: 18625415]
- Angelini C: Diagnosis and management of autoimmune myasthenia gravis. *Clin Drug Invest* 31: 1, 2011. [PMID: 21053987]
- Gilbert ME, Savino PJ: Ocular myasthenia gravis. *Int Ophthalmol Clin* 47: 93, 2007. [PMID: 18049283]
- Tremolizzo L, Giopato F, Piatti ML, et al: Myasthenia gravis mimicking stroke: a case series with sudden onset dysarthria. *Neurol Sci* 36(6): 895, 2015. [PMID: 25648108]
- Gwathmey KG, Burns TM: Myasthenia gravis. *Semin Neurol* 35: 327, 2015. [PMID: 26502757]
- García-Carrasco M, Escarcega RO, Fuentes-Alexandro S, et al: Therapeutic options in autoimmune myasthenia gravis. *Autoimmun Rev* 6: 373, 2007. [PMID: 17537383]
- Kumar V, Kaminski HJ: Treatment of myasthenia gravis. *Curr Neurol Neurosci Rep* 11: 89, 2011. [PMID: 20927659]
- Maggi L, Mantegazza R: Treatment of myasthenia gravis: focus on pyridostigmine. *Clin Drug Invest* 31: 691, 2011. [PMID: 21815707]
- Wolfe GI, Kaminski HJ, et al: Randomized trial of thymectomy in myasthenia gravis. *N Engl J Med* 375: 511, 2016. [PMID: 27509100]
- Zieliński M: Management of myasthenic patients with thymoma. *Thorac Surg Clin* 21: 47, 2011. [PMID: 21070986]
- Pénisson-Besnier I: Treatment of autoimmune myasthenia. *Rev Neurol (Paris)* 166: 400, 2010. [PMID: 19836041]
- Rózsa C, Mikor A, Kasa K, Illes Z, Komoly S: Long-term effects of combined immunosuppressive treatment on myasthenic crisis. *Eur J Neurol* 16: 796, 2009. [PMID: 19453406]
- Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. *Neurology* 68: 837, 2007. [PMID: 17353471]
- Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for myasthenia gravis. *Cochrane Database Syst Rev* 1: CD002277, 2008. [PMID: 18254004]
- Blichfeldt-Lauridsen L, Hansen BD: Anesthesia and myasthenia gravis. *Acta Anaesthesiol Scand* 56: 17, 2012. [PMID: 22091897]
- Vymazal T, Krecmerova M, Bicek V, Lischke R: Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery: a series of 117 cases. *Ther Clin Risk Manag* 11: 1593, 2015. [PMID: 26508869]
- Jani-Acsadi A, Lisak RP: Myasthenic crisis: guidelines for prevention and treatment. *J Neurol Sci* 261: 127, 2007. [PMID: 17544450]
- Hart IK, Sharshar T, Sathasivam S: Immunosuppressant drugs for myasthenia gravis. *J Neurol Neurosurg Psychiatry* 80: 5, 2009. [PMID: 19091704]
- Imai T, Suzuki S, Tsuda E, et al: Oral corticosteroid therapy and present disease status in myasthenia gravis. *Muscle Nerve* 51: 692, 2015. [PMID: 25155615]
- Ragonese P, Aridon P, Salemi G, D'Amelio M, Savettieri G: Mortality in multiple sclerosis: a review. *Eur J Neurol* 15: 123, 2008. [PMID: 18217882]
- Farez MF, Correale J: Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. *J Neurol* 258: 1197, 2011. [PMID: 21431896]
- Koch M, Uyttenboogaart M, Polman S, De Keyser J: Seizures in multiple sclerosis. *Epilepsia* 49: 948, 2008. [PMID: 18336559]
- Milo R, Miller A: Revised diagnostic criteria of multiple sclerosis. *Autoimmun Rev* 13: 518, 2014. [PMID: 24424194]
- Kragt JJ, Thompson AJ, Montalban X, et al: Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. *Neurology* 70: 1084, 2008. [PMID: 18184917]
- Swanton JK, Rovira A, Tintore M, et al: MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurol* 6: 677, 2007. [PMID: 17616439]
- Vargas DL, Tyor WR: Update on disease-modifying therapies for multiple sclerosis. *J Invest Med pii: jim-2016-000339*, 2017. [PMID: 28130412]
- Havla J, Warnke C, Derfuss T, et al: Interdisciplinary risk management in the treatment of multiple sclerosis. *Dtsch Arztebl Int* 113: 879, 2016. [PMID: 28130920]
- Le Page E, Veillard D, et al: Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOSEP): a randomised, controlled, double-blind, non-inferiority trial. *Lancet* 386: 974, 2015. [PMID: 26135706]
- Thrower BW: Relapse management in multiple sclerosis. *Neurologist* 15: 1, 2009. [PMID: 19131851]
- Heesen C, Solari A, Giordano A, Kasper J, Köpke S: Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. *J Neurol Sci* 306: 192, 2011. [PMID: 20920815]
- Fazekas F, Strasser-Fuchs S, Hommes OR: Intravenous immunoglobulin in MS: promise or failure? *J Neurol Sci* 259: 61, 2007. [PMID: 17449063]
- Goodin DS, Cohen BA, O'Connor P, et al: Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 71: 766, 2008. [PMID: 18765653]
- Castro-Borrero W, Graves D, Frohman TC, et al: Current and emerging therapies in multiple sclerosis: a systematic review. *Ther Adv Neurol Disord* 5: 205, 2012. [PMID: 22783370]
- Pucci E, Branäs P, D'Amico R, et al: Amantadine for fatigue in multiple sclerosis. *Cochrane Database Syst Rev* 1: CD002818, 2007. [PMID: 17253480]
- Casetta I, Iuliano G, Filippini G: Azathioprine for multiple sclerosis. *Cochrane Database Syst Rev* 4: CD003982, 2007. [PMID: 17943809]
- Vedula SS, Brodney-Folse S, Gal RL, Beck R: Corticosteroids for treating optic neuritis. *Cochrane Database Syst Rev* 1: CD001430, 2007. [PMID: 17253459]
- La Mantia L, Milanese C, Mascoli N, et al: Cyclophosphamide for multiple sclerosis. *Cochrane Database Syst Rev* 1: CD002819, 2007. [PMID: 17253481]
- Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G: Mitoxantrone for multiple sclerosis. *Cochrane Database Syst Rev* 5: CD002127, 2013. [PMID: 23728638]
- Farinotti M, Simi S, Di Pietrantonj C, et al: Dietary interventions for multiple sclerosis. *Cochrane Database Syst Rev* 1: CD004192, 2007. [PMID: 17253500]
- Mills RJ, Yap L, Young CA: Treatment for ataxia in multiple sclerosis. *Cochrane Database Syst Rev* 1: CD005029, 2007. [PMID: 17253537]
- Briggs SE, Gozzard P, Talbot DC: The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma. *Immunotargets Ther* 2: 31, 2013. [PMID: 27471686]
- Titulaer MJ, Lang B, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. *Lancet Neurol* 10: 1098, 2011. [PMID: 22094130]
- Joubert B, Honnorat J: Autoimmune channelopathies in paraneoplastic neurological syndromes. *Biochim Biophys Acta* 1848: 2665, 2015. [PMID: 25883091]
- Spillane J, Ermolyuk Y, Cano-Jaimez M, et al: Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca<sup>2</sup> channels. *Neurology* 84: 575, 2015. [PMID: 25589670]
- Oh SJ, Hatanaka Y, Claussen GC, Sher E: Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. *Muscle Nerve* 35: 178, 2007. [PMID: 17058271]
- Quartel A, Turbeville S, Lounsbury D: Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. *Curr Med Res Opin* 26: 1363, 2010. [PMID: 20377318]
- Titulaer MJ, Lang B, Verschuuren JJGM: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. *Lancet Neurol* 10: 1098, 2011. [PMID: 22094130]
- Titulaer MJ, Lang B, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. *Lancet Neurol* 10: 1098, 2011. [PMID: 22094130]
- Keogh M, Sedehizadeh S, Maddison P: Treatment for Lambert-Eaton myasthenic syndrome. *Cochrane Database Syst Rev* 2: CD003279, 2011. [PMID: 21328260]
- Gershanik OS: Clinical problems in late-stage Parkinson's disease. *J Neurol* 257 (Suppl 2): S288, 2010. [PMID: 21080191]
- Stamey W, Jankovic J: Impulse control disorders and pathological gambling in patients with Parkinson disease. *Neurologist* 14: 89, 2008. [PMID: 18332838]
- Factor SA: Current status of symptomatic medical therapy in Parkinson's disease. *Neurotherapeutics* 5: 164, 2008. [PMID: 18394561]
- Eberling JL, Jagust WJ, Christine CW, et al: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology* 70: 1980, 2008. [PMID: 18401019]
- Fox SH, Katzenschlager R, Lim S-Y, et al: The Movement Disorder Society evidence-based medicine review update: treatments for motor symptoms of Parkinson's disease. *Mov Disord* 26: S2, 2011. [PMID: 22021173]

## 2 SECTION 14: Neurology

67. Hickey P, Stacy M: Available and emerging treatments for Parkinson's disease: a review. *Drug Des Devel Ther* 5: 241, 2011. [PMID: 21607020]
68. Krack P, Martinez-Fernandez R, Del Alamo M, Obeso JA: Current applications and limitations of surgical treatments for movement disorders. *Mov Disord* 32: 36, 2017. [PMID: 28124435]
69. Rodriguez-Oroz MC, Moro E, Krack P: Long-term outcomes of surgical therapies for Parkinson's disease. *Mov Disord* 27: 1718, 2012. [PMID: 23208668]
70. Newman EJ, Grosset DG, Kennedy PG: The parkinsonism-hyperpyrexia syndrome. *Neurocrit Care* 10: 136, 2009. [PMID: 18712508]
71. Chumakov K, Ehrenfeld E: New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. *Clin Infect Dis* 47: 1587, 2008. [PMID: 18990066]
72. Tiffreau V, Rapin A, Serafi R, et al: Post-polio syndrome and rehabilitation. *Ann Phys Rehabil Med* 53: 42, 2010. [PMID: 20044320]
73. Boyer FC, Tiffreau V, Rapin A, et al: Post-polio syndrome: pathophysiological hypothesis, diagnosis criteria, medication therapeutics. *Ann Phys Rehabil Med* 53: 34, 2010. [PMID: 20093102]
74. Pastuszek Z, Stępień A, Tomczykiewicz K, et al: Post-polio syndrome. Cases report and review of literature. *Neurol Neurochir Pol* 51: 140, 2017. [PMID: 28209439]
75. McNalley TE, Yorkston KM, Jensen MP, et al: Review of secondary health conditions in postpolio syndrome: prevalence and effects of aging. *Am J Phys Med Rehabil* 94: 139, 2015. [PMID: 25122095]
76. Gonzalez H, Olsson T, Borg K: Management of postpolio syndrome. *Lancet Neurol* 9: 634, 2010. [PMID: 20494327]
77. Tiffreau V, Rapin A, Serafi R, et al: Post-polio syndrome and rehabilitation. *Ann Phys Rehabil Med* 53: 42, 2010. [PMID: 20044320]